Rius Medical

Dear investors,

There is no question about the incredible clinical impact cell therapies can have on the lives of patients. For drug delivery using red blood cells: Progress in clinical development is with providers like Erytech Pharma addressing cancer, Orphan Technologies addressing rare disease of metabolism MNGIE, Rubius Therapeutics addressing rare disease of metabolism Phenylketonuria and Anokion addressing autoimmune diseases like type 1 diabetes, celiac disease and Multiple Sclerosis.

However, this impact is the result of innovation that does not equate to a simple, straightforward commercialisation process. The commercialisation and management requirements of these treatments are just as complex as their innovative science. That’s because traditional production model has all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable.

Rius Medical approach with TECHNOLOGY TRANSFER as provider engagement is a significant understatement in the context of cell therapies. Unlike when dealing with traditional pharmaceutical products, providers need a much greater level of support in order to successfully operationalize and provide cell therapies, and they look to manufacturers for help. For example April 2022 Erytech Pharma made a collaboration agreement with CDMO Catalent www. The "Rius Medical upgrade" allows providers to bring new products to market faster www.

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK) www. Rius Medical solves the scientific and technical hurdles blocking access to life changing protein therapeutics (enzyme or antigen biologics) by “reprogramming stem cells” into cell therapies.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

“Lab-grown blood given to people in world-first clinical trial” is great news for Rius Medical, a preclinical biotech company developing novel therapeutics across all modalities and therapeutic areas. Traditional production models have all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable!

In this LinkedIN link www, you shall find a press release of Rius Medical, developing Advanced Manufacturing by reprogramming stem cells as a mammalian expression system for recombinant plasma proteins with excess cells that mature as needed into desired drug-loaded, cargo red blood cells. Yes, in delivering life-changing therapies to people living with rare disease, Rius Medical brings a platform-based solution with breakthrough potential to empower next generation of awesome life science developments where they can realize their visions.

In Rius Medical is an entrepreneur with a big vision who wants to create something less ordinary - something that matters, for all of us - a founder’s unshakeable intention to address a significant, pressing challenge on our planet and in our society! Products engineered with biotechnology present a collaborative space for Bioentrepreneurs and investors to address society big challenges of cancer, type 1 diabetes and other diseases. For Rius Medical, that is under ONE-Platform technology!

Many thanks and warmest regards,

Denis

Denis Demarais

Founder and CEO

Email: denisdemarais@riusmedical.de

Enabling Awesome: The journey from discovery to medical breakthrough demands imagination, speed, and focus. At Rius Medical, we empower the next generation of awesome life science developments with a platform where they can realize their visions. This approach shall revolutionize the way life science start-ups progress from idea to key data through a model that champions collaboration at the center of everything we do.

The recent McKinsey & Company report shows investors are recognizing the potential for biology to solve some of the world’s biggest problems, investing $35 billion in seed to series C biotech ventures over the past three years. An example is the earliest Leaps by Bayer 2016 investments in platform technologies like cell and gene therapies - BlueRock Therapeutics. McKinsey & Company report underscores how a foundational approach—making strategic investments in teams developing platform-based solutions with breakthrough potential—is gaining momentum and scale!

August 2019: Bayer acquired BlueRock Therapeutics to build leading position in cell therapy
June 2022: Bayer’s BlueRock Therapeutics established European Site For Cell Therapy Innovation

Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation!

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de

Dear investors,

In Rius Medical is an entrepreneur with a big vision who wants to create something less ordinary - something that matters, for all of us - a founder’s unshakeable intention to address a significant, pressing challenge on our planet and in our society! Products engineered with biotechnology present a collaborative space for Bioentrepreneurs and investors to address society big challenges of cancer, type 1 diabetes and other diseases. For Rius Medical, that is under ONE-Platform technology!

Yes, I agree that Rius Medical as a life science company is outside the investment scope of many investors. In general, Life Science investment is often perceived as high risk - the sector comprises companies that have an 85-95% failure rate on everything they attempt to invent. Even to achieve success takes about 10 to 12 years, and most biotech businesses do not have any measurable revenue for a long period of time. This view alone, yes! But that is not what Rius Medical does!

De-risking Rius Medical: 14 months to revenue by upgrading existing FDA/EMA approved biologics!
[1] Manufacture of Biologics - accelerate timelines for the development / manufacturing of molecules and disruptive technologies! The Lonza support to Bioqube Ventures www and ALSA Ventures www goes beyond due diligence of candidate biotechs by bringing tailored offering of advice and services to portfolio companies supporting de-risking early development and manufacturing of next-generation modalities. Developing and manufacturing these increasingly complex modalities require sophisticated facility design and expertise, which is often challenging to establish in-house (e.g. Rius Medical). Pnina Weitz, Global Head of Venture Capital Business Development and Relationship Management at Lonza, wants collaboration talks with Rius Medical this week. The collaboration aims to significantly increase the chances for the future success of these therapies by providing early de-risking and development and manufacturing services tailored to each molecule’s unique needs and properties.

[2] How do you see Axilium or Hadean Ventures if not Coparion PDF - a venture capital fund for young, German technology companies provided by ERP Special Fund, KfW Capital and European Investment Bank; making EUR 500,000 co-investment alongside Lead Investor EUR 500,000 investment inclusive of 20% refund from German Ministry for Economic Affairs and Climate Protection (BMWK) www? Yes, sharing the EUR 1 million requested funding between two investors. By the way, according to BMWK, the maximum “eligible investment amount for 20% refund” is EUR 500,000 per investor per year. Thus lowering the risk for investor(s) www. By December 2023, significant progress of Rius Medical is technology transfer deals to FR, Erytech Pharma (Enzyme L-Asparaginase) and USA, Travere Therapeutics parent company of CH, Orphan Technologies (Enzyme Thymidine phosphorylase) - both FDA/EMA approved biologics! Example: Travere Therapeutics (previously Retrophin) made an upfront payment of USD 90 million in cash at closing of the transaction. Orphan Technologies shareholders will remain eligible to receive up to USD 427 million in additional cash payments contingent upon the achievement of key milestones in the development and commercialisation of OT-58 www. [Encapsulation in 29 days half-life red blood cells from the patient's own blood, Phase 2 clinical trial until December 2022 at St George's, University of London www]. That’s right, Lead Investor co-investing with EUR 500,000 for 10% ownership in Rius Medical with EXIT option of EUR 5,2 million on two cell line products as technology transfer deals to third parties by December 2023!  Thereafter CDMO Lonza as a partner to Health Solutions product line with red blood cells drug delivery of enzyme or antigen!

[3] Rius Medical Go-to-Market at reduced risk
For life sciences companies, regulatory compliance never becomes any less complex and stringent. Depending on the exact nature of the work and where business is done, multiple regulatory frameworks apply www. Nonetheless this does not apply to Rius Medical! For example Sanofi EUR 308 million buyout of Kiadis natural killer cell projects www is based on iPSC technology Kiadis acquired for nothing from Cytosen a year and a half ago. The move in November 2020 by Sanofi came just four months after the French company licensed one of Kiadis’s Cytosen-derived natural killer cell projects for EUR 17.5 million up front. Rius Medical out-licensing is EUR 20 million up front each on 2x red blood cells drug delivery of FDA/EMA approved enzymes (L-Asparaginase and Thymidine phosphorylase)! Sanofi and others shall handle the regulatory compliance!

The pharmaceuticals and life sciences industry is uniquely positioned to create value for society as its innovations lay the foundation for universal health and thus prosperity. COVID-19 emphasizes the central importance of the industry for society and the economy. I hereby wish to highlight key elements that Rius Medical is doing that might not be clearly depicted in the submitted Pitch Deck. What fits best for your investment strategy, yes that is what I would like to talk on a Zoom call.

Many thanks and warmest regards,

Denis

Denis Demarais
Founder and CEO

Email: denisdemarais@riusmedical.de